ERBB2 and neoplasm: As the spectrum of HER2-targeted therapies continue to expand, including novel antibody-drug conjugates such as trastuzumab deruxtecan (which showed an objective response of 36.8% in ovarian cancers with centrally confirmed ≥+2 HER2 expression by IHC Meric-Bernstam et al., 2023), it will be important to include patients with mucinous ovarian carcinoma in further tumor-agnostic studies.